We uphold the highest standards of scientific rigor.
We will forever work to improve.
We are driven by compassion for others.
We do what is right, in the right way.
Babson Diagnostics was incubated within Siemens Healthineers beginning in 2015 and launched as an independent startup in 2017. In 2019, Babson Diagnostics opened its first CLIA-registered clinical laboratory in Austin, TX. Babson Diagnostics is now working with recognized local and national retail pharmacies to conduct clinical trials intended for publishing and peer review.
Eric Olson is CEO and founder of Babson Diagnostics. Eric previously served as VP, Portfolio & Product Management for Siemens Healthineers’ clinical laboratory business. In this role, he was globally responsible for portfolio strategy, product management, and R&D budget allocation for the company’s current and future products, including ADVIA, Centaur, Dimension, Vista, IMMULITE, and Atellica.
Eric also served as the global head of Siemens’ clinical laboratory automation and IT business, which advanced from #2 to #1 in market share during his tenure. In this role as VP, Automation & IT, he was also responsible for the company’s web properties and $1B+ in e-commerce operations.
Eric earned his Bachelor’s in Biology from the Massachusetts Institute of Technology and his Master’s in Technology Management from the University of Pennsylvania. He has a technical background in software architecture and development.
Jim Donnelly, Ph.D., DABCC, FCACB, FAACC, is Chief Scientific Officer and Vice President of Laboratory Operations for Babson Diagnostics. Jim previously served as EVP Regulatory and Clinical Affairs for Quotient Limited and Chief Scientific Officer for at Siemens Healthineers’ Diagnostics division, where he was the Global VP for the Medical, Clinical, Scientific, and Statistical Affairs groups.
Jim is also an accomplished laboratory director and academic researcher. He was Associate Professor of Pathology at NYU School of Medicine and Associate Director of Laboratory Medicine and Pathology at New York City Health and Hospitals Corporation. In New York City, he was the Medical Director for multiple clinical pathology disciplines and CLIA high complexity laboratories across Manhattan and the Bronx.
Jim completed his Ph.D. in Pharmacology and Biochemistry at The George Washington University and his MBA from the University of Ottawa. He holds his Diplomate, Clinical Chemistry, American Board of Clinical Chemists and is a Fellow of the US National Academy of Clinical Biochemistry and the Canadian Academy of Clinical Biochemistry.
Heath Marr is Laboratory Manager for Babson Diagnostics. Heath has 12 years’ experience as a Laboratory Director/Manager/Supervisor, including at Texas Oncology, Clinical Pathology Laboratory, and Schryver Medical. Heath has prior experience at 3 startup companies and in helping to open 5 brand-new laboratories. He previously served as Hematology Applications Specialist for Siemens.
Heath is an ASCP-certified Medical Technologist and earned his BS in Clinical Laboratory Science from Texas State University.
Celia Ross is Office Manager & Executive Assistant for Babson Diagnostics. She has seven years’ experience in operations and people management from a 501(c)3 nonprofit and a retail consumer cooperative.
Celia earned her BFA from the University of Oklahoma as a National Merit scholar.
Chris DiPasquale is Lead Scientist for Babson Diagnostics. He has 12 years’ experience in clinical assay R&D at Siemens with a heavy focus on reagent optimization, method integration, and verification. He has applied Six Sigma principles to innovative development projects including Vitamin D, ELF, and high-sensitivity Troponin I.
Chris earned his BS in Biotechnology & Biochemistry from Rutgers University.
Melissa Abigania is Laboratory Technician for Babson Diagnostics. She has 15 years’ laboratory experience and is a New York State certified Clinical Laboratory Technician. She contributed to an article on prenatal diagnosis published at Columbia University.
Melissa earned her AAS in Computer Programming and Health Science from the City University of New York.
Judson Cooper is a member of Babson Diagnostics’ Board of Directors and is a founding principal of Prism Ventures LLC. He has been an active investor in technology, biotechnology and healthcare companies since 1990. Mr. Cooper has co-founded eight medical technology companies, serving in senior operating and advisory positions to provide financing, recruit management and oversee corporate operations and strategy. Mr. Cooper served as Chairman of SIGA Technologies and of Lev Pharmaceuticals from 2003 until its acquisition in 2008 in a transaction valued at over $500 million.
Mr. Cooper has an MBA from the Kellogg School of Management.
Maninder “Mini” Kahlon is a member of Babson Diagnostics’ Board of Directors and is Vice Dean for the Health Ecosystem at the UT Dell Medical School, which she helped to launch. Preceding this role, Mini served as Chief Information Officer and Executive Director for UCSF’s Clinical and Translational Science Institute. Focused on advancing healthcare innovation, Dr. Kahlon has served as Vice Chair of MedTech Innovation for the Austin Chamber of Commerce Board of Directors, Founding Co-Chair of the Austin Healthcare Council, and, as of 2019, Executive Director of Factor Health, a program that builds new businesses to address the broader social and behavioral drivers of health.
Dr. Kahlon graduated from Bryn Mawr College and earned a Ph.D. in Neuroscience from the University of California, San Francisco.
Dr. Alan Wu
Dr. Alan Wu, PhD, is a member of Babson Diagnostics’ Scientific Advisory Board and is also both a Professor of Laboratory Medicine at UCSF and Chief of Clinical Chemistry and Toxicology Laboratories at San Francisco General Hospital. He was awarded the American Association for Clinical Chemistry Outstanding Contributions to Education Award in 2002, as well as the IVD Technology’s Top Ten Persons in the IVD Industry in 2005. Dr. Wu is a published author and is Editor-in-Chief of Clinical Chimica Acta.
Dr. Wu earned his B.S. degrees in Chemistry and Biology from Purdue University, and his Ph.D. in Analytical Chemistry at the University of Illinois.
Dr. Susan A. Evans
Dr. Susan A. Evans, PhD, is a member of Babson Diagnostics’ Scientific Advisory Board and is also Principal and Founder of BioDecisions Consulting. Previously, Dr. Evans served as Vice President of Scientific Affairs at Beckman Coulter. Dr. Evans previously served as President of the American Association for Clinical Chemistry (AACC). She has 30 years’ experience in diagnostics and laboratory medicine, and due to her impact in this field, was honored with AACC’s Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine in 2017.
Dr. Evans earned her Ph.D. in Chemistry from the University of Detroit.
Dr. Robert H. Christenson
Dr. Robert H. Christenson, PhD, DABCC, FACB, FACC, is a member of Babson Diagnostics’ Scientific Advisory Board and is also both Professor of Pathology and Medical and Research Technology at the University of Maryland as well as Medical Director of Core Laboratories. An international expert in cardiac biomarkers and clinical utility, he has published more than 350 peer-reviewed papers and serves as Editor-in-Chief of The Journal of Applied Laboratory Medicine. Dr. Christenson previously served as President of the American Association for Clinical Chemistry.
Dr. Christenson earned his BA in Chemistry from the University of Massachusetts and his Ph.D. in Analytical Chemistry at Florida State University.